Tocqueville Asset Management L.P. Invests $5.30 Million in Bristol Myers Squibb Company $BMY

Posted by Brian Himes on Aug 21st, 2026

Tocqueville Asset Management L.P. acquired a new position in Bristol Myers Squibb Company (NYSE:BMY – Free Report) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 91,910 shares of the biopharmaceutical company’s stock, valued at approximately $5,296,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Swiss RE Ltd. acquired a new position in Bristol Myers Squibb in the fourth quarter valued at approximately $25,000. Darwin Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $25,000. Physician Wealth Advisors Inc. grew its position in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 202 shares during the period. Bayban bought a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at $31,000. Finally, EQ Wealth Advisors LLC acquired a new position in shares of Bristol Myers Squibb during the 4th quarter valued at $32,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Guggenheim reissued a “buy” rating and set a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Truist Financial reaffirmed a “buy” rating and issued a $70.00 target price (up from $65.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Piper Sandler assumed coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued an “overweight” rating on the stock. Argus raised Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price objective for the company in a research note on Wednesday, August 5th. Finally, BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $66.06.

View Our Latest Research Report on BMY

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Bristol Myers Squibb announced a collaboration with Chai Discovery to use artificial intelligence for antibody discovery. The partnership could improve the speed and efficiency of developing new therapies, although financial terms and the near-term earnings impact were not disclosed. Chai Discovery collaboration with Bristol Myers Squibb
Positive Sentiment: An update on the Phase 1 study of navlimetostat indicates continued progress in Bristol Myers Squibb’s early-stage pipeline. The program remains experimental, so any commercial benefit is still distant and uncertain. Bristol Myers Squibb navlimetostat study update
Positive Sentiment: Hematogenix said its minimal residual disease assay supported the FDA’s accelerated approval of Bristol Myers Squibb’s ZENBEXUS™, described as the first approved CELMoD therapy for multiple myeloma. The approval could expand the company’s oncology opportunity, though accelerated approvals typically require confirmatory evidence. Hematogenix assay and ZENBEXUS approval
Positive Sentiment: Unusually heavy call-option activity, with 55,757 calls purchased—more than double the average volume—signals increased speculative interest in BMY. Options activity is not confirmation of a sustained rally and can increase volatility.
Positive Sentiment: Analyst coverage continues to characterize BMY as an attractive value stock, supported by its relatively low valuation and income potential. A separate comparison also frames Bristol Myers Squibb as a potential bargain versus AstraZeneca, though these are opinion-based assessments. Zacks BMY value-stock analysis
Neutral Sentiment: Articles discussing a covered-call strategy emphasize income generation rather than a bullish outlook for capital appreciation. The strategy may appeal to yield-focused investors but can limit upside if the shares rise sharply. Bristol Myers Squibb options income strategy
Neutral Sentiment: A report on Aktis Oncology, which has attracted interest from Bristol Myers Squibb and other large pharmaceutical companies, highlights potential future deal activity but does not announce a transaction or create an immediate financial impact for BMY. Pharmaceutical interest in Aktis Oncology

Bristol Myers Squibb Trading Down 3.1%

NYSE:BMY opened at $65.54 on Friday. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.64. The company has a market cap of $133.88 billion, a PE ratio of 14.44, a PEG ratio of 0.18 and a beta of 0.22. The firm has a 50-day moving average of $60.35 and a 200-day moving average of $59.31.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities research analysts expect that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Bristol Myers Squibb Company Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.